VHCP Management EG, LLC insider trades: Lycia Therapeutics (LYCA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where VHCP Management EG, LLC reports to the SEC
Open-market buys and sales
38 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | LYCA | ↑ Buy | 8,305 | $26.95 | $224K | By Funds | Nov 4, 2026 (2d) |
| Oct 30, 2026 | LYCA | ↑ Buy | 25,004 | $25.78 | $645K | By Funds | Oct 30, 2026 (0d) |
| Oct 27, 2026 | LYCA | ↑ Buy | 2,045,440 | $18.41 | $37.7M | By Funds | Oct 27, 2026 (0d) |
| Apr 9, 2025 | KALV | ↑ Buy | 25,000 | $9.42 | $236K | By Funds | Apr 11, 2025 (2d) |
| Feb 14, 2025 | ORKA | ↑ Buy | 122,882 | $11.45 | $1.4M | By Funds | Feb 27, 2025 (13d) |
| Feb 13, 2025 | KALV | ↑ Buy | 161,700 | $9.27 | $1.5M | By Funds | Feb 14, 2025 (1d) |
| Feb 11, 2025 | KALV | ↑ Buy | 104,489 | $9.26 | $967K | By Funds | Feb 11, 2025 (0d) |
| Feb 3, 2025 | KALV | ↑ Buy | 70,023 | $8.88 | $622K | By Funds | Feb 3, 2025 (0d) |
| Feb 8, 2024 | KALV | ↑ Buy | 86,048 | $14.62 | $1.3M | By Funds | Feb 8, 2024 (0d) |
| Jan 30, 2024 | KALV | ↑ Buy | 88,099 | $14.47 | $1.3M | By Funds | Feb 1, 2024 (2d) |
| Jan 29, 2024 | KALV | ↑ Buy | 91,804 | $14.05 | $1.3M | By Funds | Jan 29, 2024 (0d) |
| Jan 24, 2024 | KALV | ↑ Buy | 99,129 | $12.53 | $1.2M | By Funds | Jan 24, 2024 (0d) |
| Jan 19, 2024 | KALV | ↑ Buy | 143,605 | $12.55 | $1.8M | By Funds | Jan 19, 2024 (0d) |
| Jan 16, 2024 | KALV | ↑ Buy | 26,246 | $12.72 | $334K | By Funds | Jan 16, 2024 (0d) |
| Jan 10, 2024 | KALV | ↑ Buy | 137,700 | $12.54 | $1.7M | By Funds | Jan 10, 2024 (0d) |
| Jan 4, 2024 | KALV | ↑ Buy | 59,369 | $12.14 | $721K | By Funds | Jan 5, 2024 (1d) |
| Dec 29, 2023 | KALV | ↑ Buy | 519,017 | $12.46 | $6.5M | By Funds | Dec 29, 2023 (0d) |
| Oct 26, 2022 | TCDA | ↓ Sell | 6,451,540 | $0.54 | $3.5M | By Funds | Oct 26, 2022 (0d) |
| Oct 19, 2022 | TCDA | ↑ Buy | 351,866 | $10.68 | $3.8M | By Funds | Oct 20, 2022 (1d) |
| Oct 17, 2022 | TCDA | ↑ Buy | 174,966 | $11.68 | $2.0M | By Funds | Oct 17, 2022 (0d) |
| Oct 11, 2022 | TCDA | ↑ Buy | 134,214 | $11.91 | $1.6M | By Funds | Oct 11, 2022 (0d) |
| Oct 4, 2022 | TCDA | ↑ Buy | 223,100 | $11.81 | $2.6M | By Funds | Oct 6, 2022 (2d) |
| Oct 3, 2022 | TCDA | ↑ Buy | 436,923 | $10.75 | $4.7M | By Funds | Oct 3, 2022 (0d) |
| Sep 28, 2022 | TCDA | ↑ Buy | 587,214 | $8.90 | $5.2M | By Funds | Sep 28, 2022 (0d) |
| Sep 7, 2022 | TCDA | ↑ Buy | 686,712 | $11.53 | $7.9M | By Funds | Sep 7, 2022 (0d) |
| Aug 30, 2022 | TCDA | ↑ Buy | 50,000 | $12.20 | $610K | By Funds | Sep 1, 2022 (2d) |
| Jul 29, 2022 | TCDA | ↑ Buy | 18,900 | $9.21 | $174K | By Funds | Aug 2, 2022 (4d) |
| Jul 25, 2022 | TCDA | ↑ Buy | 74,199 | $9.26 | $687K | By Funds | Jul 25, 2022 (0d) |
| Jul 20, 2022 | TCDA | ↑ Buy | 150,000 | $9.18 | $1.4M | By Funds | Jul 20, 2022 (0d) |
| Jul 14, 2022 | TCDA | ↑ Buy | 94,573 | $9.88 | $935K | By Funds | Jul 14, 2022 (0d) |
| Jul 12, 2022 | VTGN | ↓ Sell | 60,000 | $0.89 | $53K | By Funds | Jul 14, 2022 (2d) |
| Jul 5, 2022 | TCDA | ↑ Buy | 88,200 | $9.61 | $847K | By Funds | Jul 6, 2022 (1d) |
| Jun 30, 2022 | TCDA | ↑ Buy | 62,870 | $9.76 | $614K | By Funds | Jun 30, 2022 (0d) |
| Jun 24, 2022 | TCDA | ↑ Buy | 492,020 | $10.37 | $5.1M | By Funds | Jun 24, 2022 (0d) |
| Jun 16, 2022 | TCDA | ↑ Buy | 5,951 | $9.69 | $58K | By funds | Jun 21, 2022 (5d) |
| Jun 14, 2022 | TCDA | ↑ Buy | 118,054 | $8.57 | $1.0M | By Funds | Jun 14, 2022 (0d) |
| Jun 9, 2022 | TCDA | ↑ Buy | 588,024 | $9.65 | $5.7M | By Funds | Jun 9, 2022 (0d) |
| Jun 6, 2022 | TCDA | ↑ Buy | 190,871 | $9.16 | $1.7M | By Funds | Jun 6, 2022 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LYCA insiders
Open-market trades in the last 12 months
About VHCP Management EG, LLC's insider trades
VHCP Management EG, LLC is a 10% owner of Lycia Therapeutics (LYCA). Since Jun 6, 2022, it has reported 36 open-market purchases worth $106.1M and 2 sales worth $3.6M on SEC Form 4. In the last 12 months: 3 buys ($38.5M).
Its filings also include conversions (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LYCA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.